EU/3/18/1985

Table of contents

About

On 22 February 2018, orphan designation (EU/3/18/1985) was granted by the European Commission to Raremoon Consulting Ltd, United Kingdom, for rusalatide acetate (also known as TP508) for the treatment of acute radiation syndrome.

The sponsorship was transferred to Raremoon Consulting Esp S.L., Spain, in May 2020.

Key facts

Active substance
Rusalatide acetate
Disease / condition
Treatment of acute radiation syndrome
Date of first decision
22/02/2018
Outcome
Positive
EU designation number
EU/3/18/1985

Sponsor's contact details

Raremoon Consulting Esp S.L.
Ronda De Sant Pere 33 Ppal 3 Y 4
08010 Barcelona
Spain
Tel. +34 93 488 0972
E-mail: sabrina@raremoonconsulting.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating